Redalyc.Vitamin B6 Status, Deficiency and Its Consequences

Total Page:16

File Type:pdf, Size:1020Kb

Redalyc.Vitamin B6 Status, Deficiency and Its Consequences Nutrición Hospitalaria ISSN: 0212-1611 info@nutriciónhospitalaria.com Grupo Aula Médica España Spinneker, A.; Sola, R.; Lemmen, V.; Castillo, M. J.; Pietrzik, K.; González-Gross, M. Vitamin B6 status, deficiency and its consequences - an overview Nutrición Hospitalaria, vol. 22, núm. 1, enero-febrero, 2007, pp. 7-24 Grupo Aula Médica Madrid, España Available in: http://www.redalyc.org/articulo.oa?id=309226714003 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Nutr Hosp. 2007;22(1):7-24 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Revisión Vitamin B6 status, deficiency and its consequences - an overview A. Spinneker**, R. Sola*, V. Lemmen*,**, M. J. Castillo*, K. Pietrzik** and M. González-Gross*,**,*** *Grupo Effects 262. Facultad de Medicina. Universidad de Granada. Spain. **Institut für Ernährungs- und Lebensmittelwis- senschaften, Rheinische Friedrichs-Wilhelms Universität Bonn. Germany. ***Facultad de Ciencias de la Actividad Física y del Deporte. Universidad Politécnica de Madrid. Spain. Abstract ESTADO DE VITAMINA B6, DEFICIENCIA Y SUS CONSECUENCIAS — UNA REVISIÓN Background: Vitamin B6 is thought to be a most versa- tile coenzyme that participates in more than 100 bioche- mical reactions. It is involved in amino acid and ho- Resumen mocysteine metabolism, glucose and lipid metabolism, Antecedentes: se piensa que la vitamina B es la coenzi- neurotransmitter production and DNA/RNA synthesis. 6 Vitamin B can also be a modulator of gene expression. ma más versátil que participa en más de 100 reacciones 6 bioquímicas. Está implicada en el metabolismo de los Nowadays, clinically evident vitamin B6 deficiency is not a common disorder, at least in the general population. aminoácidos y de la homocisteína, el metabolismo de la Nevertheless, a subclinical, undiagnosed deficiency may glucosa y los lípidos, en la producción de neurotransmi- be present in some subjects, particularly in the elderly. sores y en la síntesis de ADN/ARN. Esta vitamina tam- Objective: This review gives a complete overview over bién puede ser un modulador de la expresión génica. the metabolism and interactions of vitamin B . Further, Hoy en día, la deficiencia clínicamente evidente de vita- 6 mina B no es una afección habitual, al menos en la po- we show which complications and deficiency symptoms 6 blación general. Sin embargo, puede ocurrir una defi- can occur due to a lack of vitamin B6 and possibilities for public health and supplemental interventions. ciencia subclínica no diagnosticada en algunos Methods: The database Medline (www.ncvi.nlm.nih.gov) individuos, especialmente en los ancianos. Objetivo: esta revisión aporta una visión de conjunto was searched for terms like “vitamin B6”, “pyridoxal”, “cancer”, “homocysteine”, etc. For a complete understan- completa sobre el metabolismo y las interacciones de la vitamina B . Además, mostramos qué complicaciones y ding, we included studies with early findings from the for- 6 ties as well as recent results from 2006. These studies were síntomas por deficiencia pueden ocurrir por la falta de vitamina B y las posibilidades de intervenciones de sa- summarised and compared in different chapters. 6 Results and conclusion: In fact, it has been proposed lud pública y de suplementos. that suboptimal vitamin B status is associated with cer- Métodos: se buscó en la base de datos Medline 6 (www.ncvi.nlm.nih.gov) con los términos “vitamin B ”, tain diseases that particularly afflict the elderly popula- 6 tion: impaired cognitive function, Alzheimer’s disease, “pyridoxal”, “cancer”, “homocysteine”, etc. Para una cardiovascular disease, and different types of cancer. So- mayor comprensión, incluimos estudios con hallazgos me of these problems may be related to the elevated ho- iniciales de los años cuarenta, así como estudios recientes del año 2006. Se resumieron estos estudios y se compara- mocysteine concentrations associated to vitamin B6 defi- ciency, but there is also evidence for other mechanisms ron por capítulos diferentes. independent of homocysteine by which a suboptimal vi- Resultados y conclusión: de hecho, se ha propuesto que el estado sub-óptimo de vitamina B6 se asocia con tamin B6 status could increase the risk for these chronic diseases. ciertas enfermedades que afligen en especial a la pobla- ción anciana: función cognitiva alterada, enfermedad de (Nutr Hosp. 2007;22:7-24) Alzheimer, cardiopatía y distintos tipos de cáncer. Algu- Key words: Vitamin B . Coenzyme. Elderly. Homocystei- nos de estos problemas podrían relacionarse con concen- 6 traciones elevadas de homocisteína asociadas con una ne. Vitamin B6 deficiency. deficiencia de vitamina B6, pero también existe la eviden- cia de otros mecanismos independientes de la homociste- ína por los que un estado sub-óptimo de vitamina B6 po- Correspondence: Prof. Dr. Marcela González-Gross dría aumentar el riesgo de padecer estas enfermedades Facultad de CC de la Actividad Física y del Deporte crónicas. Universidad Politécnica de Madrid Martín Fierro, s/n 28040 Madrid (Nutr Hosp. 2007;22:7-24) E-mail: [email protected] Palabras clave: Vitamina B6. Coenzima. Anciano. Homocis- Recibido: 15-XI-2006. teína. Deficiencia de vitamina B6. Aceptado: 10-XII-2006. 7 Introduction and pyridoxamin-5´-phosphate (PMP) are the biologi- cal active coenzyme forms (fig. 1). They are water-so- Vitamin B6 sufficiency is required for optimal he- luble and can be inter-converted in normal human me- alth. This is due to the participation in many different tabolism1. PLP is the major form that is used by biochemical reactions. Vitamin B6 and its derivatives pyridoxine-dependent enzymes. These enzymes ca- are needed, especially in there coenzyme functions, talyse more than 100 essential biochemical reactions for the main metabolic pathways in the human body. in human metabolism. For that reason, it is clear that a vitamin B6 deficiency, B6 vitamers are similarly absorbed in the upper je- even in mild forms, has effects on the human metabo- junum and little in ileum, but before absorption, lism. Several diseases and impairments of health are phosphate esters must be hydrolysed by alkaline connected to the wide variety of B6 functions in su- phosphatase or other intestinal phosphatases. The boptimal status. This can also be worsened through non-phosphorylated form enters the mucosal cells by ageing. two different processes according to luminal concen- This article gets deep into metabolic functions of tration. At low concentrations, vitamers enter the cell vitamin B6 and gives an overview about associated di- by an active process regulated by requirements. At seases to vitamin B6 deficiency with new insights high concentrations, transport is by non-saturable pas- from recently published studies, including prevention sive diffusion mechanisms1. Once in the cell, vitamers and treatment potentials. are phosphorylated by ATP dependent pyridoxine ki- nase in a process referred to as metabolic trapping. The phosphorylated form can not traverse cell mem- Vitamin B6 – Chemistry, metabolism and branes and must therefore be dephosphorylated again bioavailability before traversing the basolateral membrane side of the mucosal cell. Once in the circulation, most of B6 vita- Vitamin B6 comprises a group of three related 3-hy- mers are transported to the liver where they are again droxy-2-methyl-pyrimidine derivatives. The derivati- phosphorylated to PNP, PLP or PMP, and then relea- 1,2 ve pyridoxine (PN) is an alcohol, pyridoxal (PL) is an sed to plasma . Vitamin B6 in plasma is mainly PLP aldehyde and pyridoxamine (PM) contains an amino (60%), PN (15%) and PL (14%). These vitamers cir- group. Their respective 5´-phosphate esters: pyridoxi- culate bound to albumin1. In peripheral tissues, in or- ne 5´-phosphate (PNP), pyridoxal 5´-phosphate (PLP) der to cross cell membranes, the phosphorylated Fig. 1.—Metabolic inter- conversion of pyridoxine, pyridoxal, pyridoxamine and their respective phosp- hate esters (modified after Bässler, 2002). 8 Nutr Hosp. 2007;22(1):7-24 A. Spinneker y cols. forms need to be dephosphorylated by alkaline phosp- enables the amino acid for further reactions. Some of horylase. Transport into tissue cells is by gradient dif- the reactions PLP is involved in are: transamination of fusion. This gradient is maintained thanks to the im- amino acids to keto acids (which can be then used for mediate rephosphorylation occurring inside the cells. gluconeogenesis), formation of α-aminolevuline acid Intracellular accumulation of PLP seems to be limited (a precursor of heme group), as coenzyme in serin- by intracellular protein binding capacity. In circula- palmityl-transferase (implicated in sphingomyelin tion, PLP may enter red blood cells where PLP synthesis), decarboxylation of L-amino acids (to yield bounds to haemoglobin. In red cell mass, PLP is at amines, which function as neurotransmitters, hormo- higher concentration (4 to 5 times) than in plasma. nes or biogenic amines). In the nervous system, PN- PLP increases the oxygen affinity of haemoglobin3. dependent enzymes fall into two categories: transami- Total body stores of B6 have been estimated to be as nases and L-amino acid decarboxylases. The crucial little as 167 mg4. Up to 80% of that amount is found in PLP-dependent steps of the synthesis of several neu- muscle tissue2. PLP in metabolism occurs mainly in rotransmitters are: the enzymatic decarboxylation of the liver where it is oxidized to 4-pyridoxic-acid (4- 3,4-dihydroxyphenylalanine (DOPA) to dopamine, PA) which is released and excreted. Almost 50% of the conversion of tryptophan to both nitric acid and α urinary vitamin B6 is 4-PA. In total, some 2 mg vita- serotonine, and the conversion of glutamic acid to - 10 min B6 can be excreted every day. In cases of B6 defi- aminobutyric-acid (GABA) . Another important me- ciency, excretion appears to be lower. PN is also ex- tabolic pathway is the metabolism of one-carbon creted in faeces but to a limited extent and can units.
Recommended publications
  • Molybdoproteomes and Evolution of Molybdenum Utilization
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Vadim Gladyshev Publications Biochemistry, Department of April 2008 Molybdoproteomes and evolution of molybdenum utilization Yan Zhang University of Nebraska-Lincoln, [email protected] Vadim N. Gladyshev University of Nebraska-Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/biochemgladyshev Part of the Biochemistry, Biophysics, and Structural Biology Commons Zhang, Yan and Gladyshev, Vadim N., "Molybdoproteomes and evolution of molybdenum utilization" (2008). Vadim Gladyshev Publications. 78. https://digitalcommons.unl.edu/biochemgladyshev/78 This Article is brought to you for free and open access by the Biochemistry, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Vadim Gladyshev Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Published in Journal of Molecular Biology (2008); doi: 10.1016/j.jmb.2008.03.051 Copyright © 2008 Elsevier. Used by permission. http://www.sciencedirect.com/science/journal/00222836 Submitted November 26, 2007; revised March 15, 2008; accepted March 25, 2008; published online as “Accepted Manuscript” April 1, 2008. Molybdoproteomes and evolution of molybdenum utilization Yan Zhang and Vadim N­. Gladyshev* Department of Biochemistry, University of N­ebraska–­Lincoln, Lincoln, N­E 685880664 *Corresponding author—tel 402 472-4948, fax 402 472-7842, email [email protected] Abstract The trace element molybdenum (Mo) is utilized in many life forms, where it is a key component of several enzymes involved in nitrogen, sulfur, and carbon metabolism. With the exception of nitrogenase, Mo is bound in proteins to a pterin, thus forming the molybdenum cofactor (Moco) at the catalytic sites of molybdoenzymes.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials COMPARATIVE ANALYSIS OF THE TRANSCRIPTOME, PROTEOME AND miRNA PROFILE OF KUPFFER CELLS AND MONOCYTES Andrey Elchaninov1,3*, Anastasiya Lokhonina1,3, Maria Nikitina2, Polina Vishnyakova1,3, Andrey Makarov1, Irina Arutyunyan1, Anastasiya Poltavets1, Evgeniya Kananykhina2, Sergey Kovalchuk4, Evgeny Karpulevich5,6, Galina Bolshakova2, Gennady Sukhikh1, Timur Fatkhudinov2,3 1 Laboratory of Regenerative Medicine, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of Ministry of Healthcare of Russian Federation, Moscow, Russia 2 Laboratory of Growth and Development, Scientific Research Institute of Human Morphology, Moscow, Russia 3 Histology Department, Medical Institute, Peoples' Friendship University of Russia, Moscow, Russia 4 Laboratory of Bioinformatic methods for Combinatorial Chemistry and Biology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia 5 Information Systems Department, Ivannikov Institute for System Programming of the Russian Academy of Sciences, Moscow, Russia 6 Genome Engineering Laboratory, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia Figure S1. Flow cytometry analysis of unsorted blood sample. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S2. Flow cytometry analysis of unsorted liver stromal cells. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S3. MiRNAs expression analysis in monocytes and Kupffer cells. Full-length of heatmaps are presented.
    [Show full text]
  • Pyridoxine Pyridoxal Pyridoxamine
    Vitamin B6 Pyridoxine Pyridoxal Pyridoxamine Pyridoxine 1 Introduction Dr. Gyorgy identified in 1934 a family of chemically-related compounds including pyridoxamine (PM) & pyridoxal (PL) and pyridoxine (PN). The form most commonly form is pyridoxine HCl. Phosphorylation of 5’position of B6 (PM, PL, & PN), which make PMP, PLP, & PNP. In animal, predominant of PMP & PLP; in plant foods, a glucoside form in which glucose (5’-O- [-glucopyranosyl] pyridoxine) may play as storage form of vitamin. Pyridoxine 2 1 Pyridoxine 3 bacterial alanine racemase Pyridoxine 4 2 Pyridoxine 5 Introduction Vitamin B6 is one of the most versatile enzyme (>100 enzymes) cofactors. Pyridoxal is the predominant biologically active form (PLP). (More inborn error???) Pyridoxal phosphate (PLP) is a cofactor 1. in the metabolism of amino acids and neurotransmitters; 2. in the breakdown of glycogen; 3. bind to steroid hormone receptors and may have a role in regulating steroid hormone action; 4. in the immune system Pyridoxine 6 3 Chemistry Name: pyridoxine, pyridoxal & pyridoxamine, vitamin B6 Structure: 2-methyl-3-hydroxy5-hydroxy methyl pyridines. Chemistry & physical property property: Vitamin B6s are readily soluble in water, stable in acid, unstable in alkali, is fairly easily destroyed with UV light, e.g. sunlight. Stability --- pyridoxine > pyridoxal or pyridoxamine Pyridoxine 7 Bioavailability Complxed form B6 poorly digested B6 can be condensed with peptide lysyl or cysteinyl residues during food processing (e.g. cooking) thus, reduced the utilization of B6. Plants contain complexed forms bioavailability of B6 in animal products tends to be greater than in the plant materials. Pyridoxine 8 4 Metabolism --- Absorption Vitamin B6 is readily absorbed in the small intestine.
    [Show full text]
  • An Introduction to Nutrition and Metabolism, 3Rd Edition
    INTRODUCTION TO NUTRITION AND METABOLISM INTRODUCTION TO NUTRITION AND METABOLISM third edition DAVID A BENDER Senior Lecturer in Biochemistry University College London First published 2002 by Taylor & Francis 11 New Fetter Lane, London EC4P 4EE Simultaneously published in the USA and Canada by Taylor & Francis Inc 29 West 35th Street, New York, NY 10001 Taylor & Francis is an imprint of the Taylor & Francis Group This edition published in the Taylor & Francis e-Library, 2004. © 2002 David A Bender All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging in Publication Data Bender, David A. Introduction to nutrition and metabolism/David A. Bender.–3rd ed. p. cm. Includes bibliographical references and index. 1. Nutrition. 2. Metabolism. I. Title. QP141 .B38 2002 612.3′9–dc21 2001052290 ISBN 0-203-36154-7 Master e-book ISBN ISBN 0-203-37411-8 (Adobe eReader Format) ISBN 0–415–25798–0 (hbk) ISBN 0–415–25799–9 (pbk) Contents Preface viii Additional resources x chapter 1 Why eat? 1 1.1 The need for energy 2 1.2 Metabolic fuels 4 1.3 Hunger and appetite 6 chapter 2Enzymes and metabolic pathways 15 2.1 Chemical reactions: breaking and
    [Show full text]
  • Chemoprotective Role of Molybdo-Flavoenzymes Against
    Journal of the Association of Arab Universities for Basic and Applied Sciences (2016) xxx, xxx–xxx University of Bahrain Journal of the Association of Arab Universities for Basic and Applied Sciences www.elsevier.com/locate/jaaubas www.sciencedirect.com ORIGINAL ARTICLE Chemoprotective role of molybdo-flavoenzymes against xenobiotic compounds Khaled S. Al Salhen * Chemistry Department, Sciences College, Omar Al-Mukhtar University, El-beida, Libya Received 18 November 2015; revised 9 February 2016; accepted 23 February 2016 KEYWORDS Abstract Aldehyde oxidase (AO) and xanthine oxidoreductase (XOR) are molybdo-flavoenzymes Aldehyde oxidase; (MFEs) involved in the oxidation of hundreds of many xenobiotic compounds of which are drugs Xanthine oxidoreductase; and environmental pollutants. Mutations in the XOR and molybdenum cofactor sulfurase (MCS) Chemoprotection and Dro- genes result in a deficiency of XOR or dual AO/XOR deficiency respectively. At present despite AO sophila melanogaster and XOR being classed as detoxification enzymes the definitive experimental proof of this has not been assessed in any animal thus far. The aim of this project was to evaluate ry and ma-l strains of Drosophila melanogaster as experimental models for XOR and dual AO/XOR deficiencies respec- tively and to determine if MFEs have a role in the protection against chemicals. In order to test the role of the enzymes in chemoprotection, MFE substrates were administered to Drosophila in media and survivorship was monitored. It was demonstrated that several methylated xanthines were toxic to XOR-deficient strains. In addition a range of AO substrates including N-heterocyclic pol- lutants and drugs were significantly more toxic to ma-l AO-null strains.
    [Show full text]
  • Diseases Catalogue
    Diseases catalogue AA Disorders of amino acid metabolism OMIM Group of disorders affecting genes that codify proteins involved in the catabolism of amino acids or in the functional maintenance of the different coenzymes. AA Alkaptonuria: homogentisate dioxygenase deficiency 203500 AA Phenylketonuria: phenylalanine hydroxylase (PAH) 261600 AA Defects of tetrahydrobiopterine (BH 4) metabolism: AA 6-Piruvoyl-tetrahydropterin synthase deficiency (PTS) 261640 AA Dihydropteridine reductase deficiency (DHPR) 261630 AA Pterin-carbinolamine dehydratase 126090 AA GTP cyclohydrolase I deficiency (GCH1) (autosomal recessive) 233910 AA GTP cyclohydrolase I deficiency (GCH1) (autosomal dominant): Segawa syndrome 600225 AA Sepiapterin reductase deficiency (SPR) 182125 AA Defects of sulfur amino acid metabolism: AA N(5,10)-methylene-tetrahydrofolate reductase deficiency (MTHFR) 236250 AA Homocystinuria due to cystathionine beta-synthase deficiency (CBS) 236200 AA Methionine adenosyltransferase deficiency 250850 AA Methionine synthase deficiency (MTR, cblG) 250940 AA Methionine synthase reductase deficiency; (MTRR, CblE) 236270 AA Sulfite oxidase deficiency 272300 AA Molybdenum cofactor deficiency: combined deficiency of sulfite oxidase and xanthine oxidase 252150 AA S-adenosylhomocysteine hydrolase deficiency 180960 AA Cystathioninuria 219500 AA Hyperhomocysteinemia 603174 AA Defects of gamma-glutathione cycle: glutathione synthetase deficiency (5-oxo-prolinuria) 266130 AA Defects of histidine metabolism: Histidinemia 235800 AA Defects of lysine and
    [Show full text]
  • AN ABSTRACT of the THESIS of Kerry Elizabeth Martinson for The
    AN ABSTRACT OF THE THESIS OF Kerry Elizabeth Martinson for the degree of Master of Science in Nutrition and Food Management presented on March 11.1994. Title: Changes in Plasma Pyridoxal 5'- Phosphate and Red Blood Cell Pvridoxal 5'-Phosphate Concentration during an Oral Glucose Tolerance Test in Persons with Diabetes Mellitus. Abstract approved: _^ James E. Leklem, PhD. The purpose of this study was to determine the relationship between the overall changes in concentration of plasma pyridoxal S'-phosphate (PLP), red blood cell PLP (rbc PLP) and plasma glucose during an oral glucose tolerance test (OGTT) in persons with diabetes mellitus (DM), and to test the hypothesis that the decrease in plasma PLP con- centration that occurs with increasing plasma glucose would be explained by a subse- quent increase in rbc PLP concentration. A second objective was to compare the distri- bution of PLP between the red blood cell and the plasma (as measured by the rbc PLP/ plasma PLP ratio) in persons with diabetes to the distribution in non-diabetic controls. The third objective was to measure fasting plasma alkaline phosphatase (AP) activity, and to compare it to fasting plasma PLP concentrations, fasting rbc PLP concentrations, and the rbc PLP/plasma PLP ratio. The purpose of this third objective was to test the hypothesis that an increased plasma AP activity in persons with DM would be associated with decreased plasma PLP and increased rbc PLP concentrations. The study included 8 persons (3F; 5M) with insulin dependent diabetes mellitus (IDDM), 9 persons (5F; 4M) with non-insulin dependent diabetes mellitus (NIDDM) and 18 healthy control individuals (9F; 9M).
    [Show full text]
  • Index of Recommended Enzyme Names
    Index of Recommended Enzyme Names EC-No. Recommended Name Page 1.2.1.10 acetaldehyde dehydrogenase (acetylating) 115 1.2.1.38 N-acetyl-y-glutamyl-phosphate reductase 289 1.2.1.3 aldehyde dehydrogenase (NAD+) 32 1.2.1.4 aldehyde dehydrogenase (NADP+) 63 1.2.99.3 aldehyde dehydrogenase (pyrroloquinoline-quinone) 578 1.2.1.5 aldehyde dehydrogenase [NAD(P)+] 72 1.2.3.1 aldehyde oxidase 425 1.2.1.31 L-aminoadipate-semialdehyde dehydrogenase 262 1.2.1.19 aminobutyraldehyde dehydrogenase 195 1.2.1.32 aminomuconate-semialdehyde dehydrogenase 271 1.2.1.29 aryl-aldehyde dehydrogenase 255 1.2.1.30 aryl-aldehyde dehydrogenase (NADP+) 257 1.2.3.9 aryl-aldehyde oxidase 471 1.2.1.11 aspartate-semialdehyde dehydrogenase 125 1.2.1.6 benzaldehyde dehydrogenase (deleted) 88 1.2.1.28 benzaldehyde dehydrogenase (NAD+) 246 1.2.1.7 benzaldehyde dehydrogenase (NADP+) 89 1.2.1.8 betaine-aldehyde dehydrogenase 94 1.2.1.57 butanal dehydrogenase 372 1.2.99.2 carbon-monoxide dehydrogenase 564 1.2.3.10 carbon-monoxide oxidase 475 1.2.2.4 carbon-monoxide oxygenase (cytochrome b-561) 422 1.2.1.45 4-carboxy-2-hydroxymuconate-6-semialdehyde dehydrogenase .... 323 1.2.99.6 carboxylate reductase 598 1.2.1.60 5-carboxymethyl-2-hydroxymuconic-semialdehyde dehydrogenase . 383 1.2.1.44 cinnamoyl-CoA reductase 316 1.2.1.68 coniferyl-aldehyde dehydrogenase 405 1.2.1.33 (R)-dehydropantoate dehydrogenase 278 1.2.1.26 2,5-dioxovalerate dehydrogenase 239 1.2.1.69 fluoroacetaldehyde dehydrogenase 408 1.2.1.46 formaldehyde dehydrogenase 328 1.2.1.1 formaldehyde dehydrogenase (glutathione)
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • The Four Aldehyde Oxidases of Drosophila Melanogaster Have
    © 2014. Published by The Company of Biologists Ltd | The Journal of Experimental Biology (2014) 217, 2201-2211 doi:10.1242/jeb.102129 RESEARCH ARTICLE The four aldehyde oxidases of Drosophila melanogaster have different gene expression patterns and enzyme substrate specificities Zvonimir Marelja1, Miriam Dambowsky1, Marco Bolis2, Marina L. Georgiou1, Enrico Garattini2, Fanis Missirlis3,* and Silke Leimkühler1,* ABSTRACT Moco of eukaryotic AOXs contains an equatorial sulfur ligand In the genome of Drosophila melanogaster, four genes coding for required for the catalytic activity of the enzymes (Wahl and aldehyde oxidases (AOX1–4) were identified on chromosome 3. Rajagopalan, 1982; Bray, 1988; Hille, 1996). Phylogenetic analysis showed that the AOX gene cluster evolved via Most animal and plant genomes contain AOX gene clusters that independent duplication events in the vertebrate and invertebrate arose from a series of duplication events from a common XOR lineages. The functional role and the substrate specificity of the ancestor (Forrest et al., 1956; Nash and Henderson, 1982; distinct Drosophila AOX enzymes is unknown. Two loss-of-function Rodríguez-Trelles et al., 2003; Garattini et al., 2008). Rodents and mutant alleles in this gene region, low pyridoxal oxidase (Polpo) and marsupials contain the largest number of AOX functional genes aldehyde oxidase-1 (Aldox-1n1) are associated with a phenotype (AOX1, AOX3, AOX4 and AOX3L1), whereas the human genome characterized by undetectable AOX enzymatic activity. However, the contains one single and functional AOX1 gene (hAOX1) and two genes involved and the corresponding mutations have not yet been non-functional pseudogenes, representing the vestiges of the mouse identified. In this study we characterized the activities, substrate AOX3 and AOX3L1 orthologs (Garattini et al., 2003; Garattini et al., specificities and expression profiles of the four AOX enzymes in D.
    [Show full text]
  • Introduction to Enzymes What Is Enzymes?
    Introduction to Enzymes Enzyme Engineering What is enzymes? Life depends on well-orchestrated series of chemical reactions : E. coli has 4288 proteins, 2656 of which are characterized, and 64% (1701) of the characterized ones code enzymes Chemical reactions are far slow to maintain life Living system has designed catalysts to fasten the specific reactions 1 1.2 History of enzyme study Rock and key model Fig. 1.1 Demonstrated that enzymes do not require a cell Enzyme is proved to be a protein 1957, Myoglobin structure was deduced by X-ray crystallography Kendrew 1963, The first aa sequence of enzyme, ribonuclease was reported 1965, The first enzyme structure of lysozyme was reported 2 1.2 History of enzyme study 1958, “Induced fit” model was proposed, Koshland 1965, “Allosteric model” of enzyme was porposed, Monod 1969, the first chemical synthesis of an enzyme was reported, proving an enzyme is a protein Mechanisms of thousands enzymes have been studied by X-ray crystallography and NMR DNA recombinant methods were used to overproduce enzymes and to pinpoint the important amino acids 2004, the first computer designed enzyme was reported Kaplan, J. and DeGrado, W. F. (2004) Proc. Natl. Acad. Sci. USA 101, 11566-11570 3 1.2 History of enzyme study Catalytic biological molecules other than conventional enzymes Antibody RNA (Ribozyme) : Usually involved in RNA processing (phosphate ester hydrolysis)-Cech, 1986 As short as 30 nucleotide (hammerhead ribozyme)-Fig. 1.3 1.3 Properties of enzymes I. Catalytic power 17 It increases the rate as much as 10 fold It operates in moderate temperature and neutral pH (Enzymes from archeabacteria are exceptions) Extreme example is Nitrogen fixation (N2 to ammonia) 700 ~ 900K, 100 ~ 900atm with iron catalysts vs.
    [Show full text]